• The primary objective of this study is to gather additional, longer-term safety data in subjects who participated in the PREDECESSOR STUDY. A limited amount of effectiveness data will also be collected. [ Time Frame: 4 Years ] [ Designated as safety issue: Yes ]
  

This will be a multicenter study conducted only at the clinical sites that participated in the PREDECESSOR STUDY.

Written, informed consent will be obtained prior to performing any study procedures. Enrollment will be limited to only those subjects who were in either the Control or Treatment groups of the PREDECESSOR STUDY.

The present study will extend the follow-up evaluation of subjects from the PREDECESSOR STUDY to 3 years post-treatment for the Control Subjects and 5 years post-treatment for Alair-Treated Subjects. These evaluations will consist of two (Control Group) to four (Alair Group) additional study visits corresponding to the two-year, three-year, four-year and five-year time points following completion of Alair treatments (or similar time point for control subjects) in the PREDECESSOR STUDY. For consistency with the PREDECESSOR STUDY, ideally the subject's drug therapy should continue to be consistent with GINA Guidelines for the severity of the subject's asthma. Any changes in maintenance levels of asthma medications should be documented.

The goal of this follow-on study is to enroll all subjects who participated in the PREDECESSOR STUDY. Inclusion of subjects from the treatment arm will allow for the assessment of long-term safety of the Alair procedure for up to 5 years post treatment with the Alair System. Inclusion of subjects from the Control arm will allow for appropriate analysis of long-term effectiveness data for up to 3 years post "treatment".